UPDATE | June 27, 2026

PharmTech’s regulatory roundup for May 2026

  • MAIL

PharmTech's May 2026 Regulatory Roundup covers the FDA's launch of one-day inspections, Elsa 4.0 AI upgrade, and final CMC flexibility guidance for cell and gene therapies — which Samsung Biologics' Abigail De La Pena Garcia called "a significant step forward" formalizing a "more flexible and scientifically driven regulatory approach."


Read the full roundup for a complete breakdown of the month's regulatory developments.

PharmTech's May 2026 Regulatory Roundup covers the FDA's launch of one-day inspections, Elsa 4.0 AI upgrade, and final CMC flexibility guidance for cell and gene therapies — which Samsung Biologics' Abigail De La Pena Garcia called "a significant step forward" formalizing a "more flexible and scientifically driven regulatory approach."


Read the full roundup for a complete breakdown of the month's regulatory developments.

Share article

  • MAIL

Related Content

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Interests
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required